Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease

References

• Palmer M , Adami HO , Bergstrom R , Akerstrom G , Ljunghall S. Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987;102:1–7.
   PubMedGoogle Scholar
• Hedback G, Tisell LE, Bengtsson BA, Hedman I, Oden A. Premature death in patients operated on for primary hyperparathyroidism. World J Surg 1990;14:829–35.
   PubMed Web of Science ®Google Scholar
• Sivula A, Ronni-Sivula H. Natural history of treated primary hyperparathyroidism. Surg Clin North Am 1987;67:329–41.
   PubMed Web of Science ®Google Scholar
• Palmer M, Adami HO, Bergstrom R, Jakobsson S, Akerstrom G, Ljunghall S. Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet 1987;1:59–62.
   PubMed Web of Science ®Google Scholar
• Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O'Fallon WM, Melton LJ, III. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998;104:115–22.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 2003;27:216–22.
   PubMedGoogle Scholar
• Soreide JA, van Heerden JA, Grant CS, Yau LC, Schleck C, Ilstrup DM. Survival after surgical treatment for primary hyperparathyroidism. Surgery 1997;122:1117–23.
   PubMed Web of Science ®Google Scholar
• Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease–a review. Eur Heart J 2004;25:1776–87.
   PubMed Web of Science ®Google Scholar
• Rienstra M, Lubitz SA, Zhang ML, Cooper RR, Ellinor PT. Elevation of parathyroid hormone levels in atrial fibrillation. J Am Coll Cardiol 2011;57:2542–3.
   PubMedGoogle Scholar
• Ogino K, Burkhoff D, Bilezikian JP. The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology 1995;136:3024–30.
   PubMed Web of Science ®Google Scholar
• Walker MD, Fleischer JB, Di Tullio MR, Homma S, Rundek T, Stein EM, Zhang C, Taggart T, McMahon DJ, Silverberg SJ. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2010;95:2172–9.
   PubMed Web of Science ®Google Scholar
• Vestergaard H, Ostergaard KL. Normocalcemia and persistent elevated serum concentrations of 1–84 parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of increased morbidity from cardiovascular disease. World J Surg 2002;26:657–60.
   PubMedGoogle Scholar
• Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344: 1434–41.
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk – a meta-analysis. Osteoporos Int 2007;18:45–57.
   PubMed Web of Science ®Google Scholar
• Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Gluer CC. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 2009;24:726–36.
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207–15.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710–8.
   PubMed Web of Science ®Google Scholar
• Daggubati S, Parks JR, Overton RM, Cintron G, Schocken DD, Vesely DL. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. Cardiovasc Res 1997;36:246–55.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ, Dargie HJ. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001;86:21–6.
   PubMed Web of Science ®Google Scholar
• Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003;24:341–56.
   PubMed Web of Science ®Google Scholar
• Almqvist EG, Becker C, Bondeson AG, Bondeson L, Svensson J, Svensson SE. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism. Clin Endocrinol (Oxf) 2006;65:760–6.
   PubMedGoogle Scholar
• Ogard CG, Engelmann MD, Kistorp C, Nielsen SL, Vestergaard H. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005;63:493–8.
   PubMedGoogle Scholar
• Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003; 24:2054–60.
   PubMed Web of Science ®Google Scholar
• Svensson P, de FU, Niklasson U, Hansson LO, Ostergren J. Plasma NT-proBNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood Press 2005;14:99–106.
   PubMed Web of Science ®Google Scholar
• Kruger R, Schutte R, Huisman HW, Hindersson P, Olsen MH, Schutte AE. N-terminal prohormone B-type natriuretic peptide and cardiovascular function in Africans and Caucasians: the SAfrEIC study. Heart Lung Circ 2012;21:88–95.
   PubMedGoogle Scholar